- Email: [email protected]
5175101 Recombinant restriction enzyme SAU3AI
326
PATENT ABSTRACTS
5175097 EXPRESSION AND DIAGNOSTIC USE OF GAG-1 ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO HIV Susan M Watanabe, Wesley L Cosand, Susan McArdle, Pamela Ward assigned to Genetic Systems Corporation lmmunologically reactive gag proteins of LAV/HTLV-III are expressed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising pGAG- 1. Preferred signals for expression are selected from an inducible and/or suppressible operon, such as the trp operon. The gag proteins are isolated from the bacterial host and are utilized in diagnostic assays which detect the presence of LAV/HTLV-III antigens or antibodies immunologically reactive with LAV/HTLV-III. Further, the proteins produced by the method disclosed may be used as a vaccine against infection by the causative virus for acquired immune deficiency syndrome.
5175098 EXPRESSION AND DIAGNOSTIC USE OF GAG ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO HIV Susan M Watanabe, Wesley L Cosand, Susan McArdle, Pamela Ward assigned to Genetic Systems Corporation Immunologically reactive gag proteins of LAV are expresesed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising a portion of the gag region of LAV. Preferred signals for expression are selected from an inducible and/or suppressible operon, such as the trp operon. The gag proteins are isolated from the bacterial host and are utilized in diagonstic assays which detect the presence of LAV antigens or antibodies immunologically reactive with LAV. Further, the proteins produced by the method disclosed may be used as a vaccine
against infection by the caustive virus for acquired immune deficiency syndrome.
5175099 RETROVIRUS-MEDIATED SECRETION OF RECOMBINANT PRODUCTS John Wills assigned to Research Corporation Technologies Inc The present invention is directed to replicable expression vectors for producing fusion proteins which are secreted in membraneous particles budded from the cell membrane. In particular these vectors express a hybrid gene product composed of a modified retrovirus gag gene fused to a heterologous gene, or any part thereof, wherein the gag gene modification is sufficient to enable a cell to produce the hybrid gene product in a membraneous particle by budding from the cell membrane into the culture medium or extracellular space, a process known as retrovirusmediated secretion. The minimum gag sequences needed to obtain particle formation are described. The invention also provides hosts containing the expression vectors, and the fusion proteins produced by the vectors. Further the invention provides the membraneous particles produced by retrovirus-mediated secretion and uses of these particles for protein purification and in therapeutics. 5175101 RECOMBINANT RESTRICTION ENZYME SAU3AI Friedrich Gotz, Stefan Seeber, Tfederal Republic Of Germana assigned to Boehringer Mannheim GmbH The invention concerns a DNA which contains (I) at least one of the two regions of the nucleotide sequence SEQ ID NO: 1 coding for a protein with a Sau3AI methylase activity or for a protein with a Sau3Al endonuclease activity. (2) a sequence corresponding to the DNA from (1) within the scope of the degeneration of the genetic code or (3) a sequence which hybridizes under stringent hybridization conditions with a DNA from (1) or (2). In addition a vector is disclosed which contains a DNA according to the present invention, in particular under the control of a regulatable closed promoter, as well as microorganisms which are transformed with one or
327
P A T E N T ABSTRACTS
several vectors according to the present invention and the isolation of recombinant Sau3AI endonuclease from the transformed microorganisms.
5175102 MODIFICATION OF PLANT VIRUSES OR THEIR EFFECTS David C Baulcombe, Bryan D Harrison, Michael W Bevan, Michael A Mayo, Cambridge, United Kingdom assigned to Agricultural Genetics Company Limited The invention relates to a method of modifying a plant virus or its effects, which comprises incorporating genetic material into a plant and infecting said plant with a plant virus, whereby expression of the incorporated genetic material modifies the plant virus or its effects. In a preferred embodiment, expression in the plant of the incorporated genetic material causes attenuation of the symptoms of attack on the plant by a plant virus.
5175103 PREPARATION OF PURE CULTURES OF POST-MITOTIC HUMAN NEURONS Virginia Lee, Samuel Pleasure assigned to Trustees of University of Pennsylvania NTera 2/cl.D1 (NT2) cells, a human teratocarcinoma cell line, were manipulated following retinoic acid (RA) treatment to yield)95% pure cultures of neuronal cells (NT2-N cells). This culture method is capable of yielding sufficient highly differentiated post-mitotic NT2-N cells for both biochemical and molecular biological studies. NT2 cells can be transfected efficiently and the transfected gene products can be expressed in both NT2 and NT2-N cells.
5175104 RECOMBINANT DNA AND A PROCESS FOR PRODUCING PHOSPHOTRANSACETYLASE Matsuyama Asahi, Otake Hideko, Nakano Eiichi, Noda, Japan assigned to Kikkoman Corporation
A novel recombinant DNA is characterized in that DNA containing a gene encoding phosphotransacetylase has been inserted into vector DNA. The recombinant D N A can be obtained by culturing in medium E. coli 1100 (pPT200) (FERM BP-2195) belonging to the genus Escherichia which contains a recombinant D N A obtained by inserting DNA containing a gene coding for phosphotransacetylase into vector DNA and is capable of producing phosphotransacetylase, and collecting phosphotransacetylase from the culture.
5175105 PROCESS FOR THE PRODUCTION OF UROKINASE USING SACCHAROMYES CEREVISIAE Bernd Meyhack, Jutta Heim, Rolf Burgi, Magden, Switzerland assigned to Ciba-Geigy Corporation Novel human plasminogen activators of the urokinase type are produced by yeast cells transformed with a hybrid vector comprising a DNA sequence coding for said human plasminogen activator. Novel hybrid vectors, yeast hosts transformed with such hybrid vectors and processes for the production thereof are also provided.
5175108 PLASMIDS FROM CORYNEBACTERIUM GLUTAMICUM AND PLASMID VECTORS DERIVED THEREFROM Frank Bachmann, Hans J Kutzner, Han Sonnen, Georg Thierbach, Petra-Sabine Kautz, Alfred Puhler, Andreas Schaefer, Moerfelden Waldorf, Federal Republic Of Germany assigned to Degussa Aktiengesellschaft The present invention relates to new plasmids isolated from Corynebacterium glutamicum, plasmid pGA 1 and pGA2, which are compatible with one another. In addition, the present invention relates to recombinant plasmids and to plasmid vectors (shuttle vectors) containing the new plasmids. The plasmids and plasmid vectors of the present invention are suitable for use with genetic engineering to improve bacteria strains.
PATENT ABSTRACTS
5175097 EXPRESSION AND DIAGNOSTIC USE OF GAG-1 ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO HIV Susan M Watanabe, Wesley L Cosand, Susan McArdle, Pamela Ward assigned to Genetic Systems Corporation lmmunologically reactive gag proteins of LAV/HTLV-III are expressed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising pGAG- 1. Preferred signals for expression are selected from an inducible and/or suppressible operon, such as the trp operon. The gag proteins are isolated from the bacterial host and are utilized in diagnostic assays which detect the presence of LAV/HTLV-III antigens or antibodies immunologically reactive with LAV/HTLV-III. Further, the proteins produced by the method disclosed may be used as a vaccine against infection by the causative virus for acquired immune deficiency syndrome.
5175098 EXPRESSION AND DIAGNOSTIC USE OF GAG ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO HIV Susan M Watanabe, Wesley L Cosand, Susan McArdle, Pamela Ward assigned to Genetic Systems Corporation Immunologically reactive gag proteins of LAV are expresesed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising a portion of the gag region of LAV. Preferred signals for expression are selected from an inducible and/or suppressible operon, such as the trp operon. The gag proteins are isolated from the bacterial host and are utilized in diagonstic assays which detect the presence of LAV antigens or antibodies immunologically reactive with LAV. Further, the proteins produced by the method disclosed may be used as a vaccine
against infection by the caustive virus for acquired immune deficiency syndrome.
5175099 RETROVIRUS-MEDIATED SECRETION OF RECOMBINANT PRODUCTS John Wills assigned to Research Corporation Technologies Inc The present invention is directed to replicable expression vectors for producing fusion proteins which are secreted in membraneous particles budded from the cell membrane. In particular these vectors express a hybrid gene product composed of a modified retrovirus gag gene fused to a heterologous gene, or any part thereof, wherein the gag gene modification is sufficient to enable a cell to produce the hybrid gene product in a membraneous particle by budding from the cell membrane into the culture medium or extracellular space, a process known as retrovirusmediated secretion. The minimum gag sequences needed to obtain particle formation are described. The invention also provides hosts containing the expression vectors, and the fusion proteins produced by the vectors. Further the invention provides the membraneous particles produced by retrovirus-mediated secretion and uses of these particles for protein purification and in therapeutics. 5175101 RECOMBINANT RESTRICTION ENZYME SAU3AI Friedrich Gotz, Stefan Seeber, Tfederal Republic Of Germana assigned to Boehringer Mannheim GmbH The invention concerns a DNA which contains (I) at least one of the two regions of the nucleotide sequence SEQ ID NO: 1 coding for a protein with a Sau3AI methylase activity or for a protein with a Sau3Al endonuclease activity. (2) a sequence corresponding to the DNA from (1) within the scope of the degeneration of the genetic code or (3) a sequence which hybridizes under stringent hybridization conditions with a DNA from (1) or (2). In addition a vector is disclosed which contains a DNA according to the present invention, in particular under the control of a regulatable closed promoter, as well as microorganisms which are transformed with one or
327
P A T E N T ABSTRACTS
several vectors according to the present invention and the isolation of recombinant Sau3AI endonuclease from the transformed microorganisms.
5175102 MODIFICATION OF PLANT VIRUSES OR THEIR EFFECTS David C Baulcombe, Bryan D Harrison, Michael W Bevan, Michael A Mayo, Cambridge, United Kingdom assigned to Agricultural Genetics Company Limited The invention relates to a method of modifying a plant virus or its effects, which comprises incorporating genetic material into a plant and infecting said plant with a plant virus, whereby expression of the incorporated genetic material modifies the plant virus or its effects. In a preferred embodiment, expression in the plant of the incorporated genetic material causes attenuation of the symptoms of attack on the plant by a plant virus.
5175103 PREPARATION OF PURE CULTURES OF POST-MITOTIC HUMAN NEURONS Virginia Lee, Samuel Pleasure assigned to Trustees of University of Pennsylvania NTera 2/cl.D1 (NT2) cells, a human teratocarcinoma cell line, were manipulated following retinoic acid (RA) treatment to yield)95% pure cultures of neuronal cells (NT2-N cells). This culture method is capable of yielding sufficient highly differentiated post-mitotic NT2-N cells for both biochemical and molecular biological studies. NT2 cells can be transfected efficiently and the transfected gene products can be expressed in both NT2 and NT2-N cells.
5175104 RECOMBINANT DNA AND A PROCESS FOR PRODUCING PHOSPHOTRANSACETYLASE Matsuyama Asahi, Otake Hideko, Nakano Eiichi, Noda, Japan assigned to Kikkoman Corporation
A novel recombinant DNA is characterized in that DNA containing a gene encoding phosphotransacetylase has been inserted into vector DNA. The recombinant D N A can be obtained by culturing in medium E. coli 1100 (pPT200) (FERM BP-2195) belonging to the genus Escherichia which contains a recombinant D N A obtained by inserting DNA containing a gene coding for phosphotransacetylase into vector DNA and is capable of producing phosphotransacetylase, and collecting phosphotransacetylase from the culture.
5175105 PROCESS FOR THE PRODUCTION OF UROKINASE USING SACCHAROMYES CEREVISIAE Bernd Meyhack, Jutta Heim, Rolf Burgi, Magden, Switzerland assigned to Ciba-Geigy Corporation Novel human plasminogen activators of the urokinase type are produced by yeast cells transformed with a hybrid vector comprising a DNA sequence coding for said human plasminogen activator. Novel hybrid vectors, yeast hosts transformed with such hybrid vectors and processes for the production thereof are also provided.
5175108 PLASMIDS FROM CORYNEBACTERIUM GLUTAMICUM AND PLASMID VECTORS DERIVED THEREFROM Frank Bachmann, Hans J Kutzner, Han Sonnen, Georg Thierbach, Petra-Sabine Kautz, Alfred Puhler, Andreas Schaefer, Moerfelden Waldorf, Federal Republic Of Germany assigned to Degussa Aktiengesellschaft The present invention relates to new plasmids isolated from Corynebacterium glutamicum, plasmid pGA 1 and pGA2, which are compatible with one another. In addition, the present invention relates to recombinant plasmids and to plasmid vectors (shuttle vectors) containing the new plasmids. The plasmids and plasmid vectors of the present invention are suitable for use with genetic engineering to improve bacteria strains.